Abstract
Since women with AMH levels below current limits of detection often still respond to ovulation induction, low limits of currently widely utilized anti-Müllerian hormone (AMH) assays (∼0.16ng/mL) are clinically limiting in women with low functional ovarian reserve (LFOR). We, therefore, assessed whether a mores sensitive AMH assay may improve prediction of treatment outcomes in LFOR.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
